secwatch.observer — SEC 8-K summary
======================================

Issuer:     Natera, Inc. (NTRA)
CIK:        0001604821
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001104659-25-107727
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Natera Q3 revenue up 35% to $592M; raises FY2025 guidance by $160M midpoint
---------------------------------------------------------------------------

- Revenue $592.2M (+34.7% YoY); product rev +35.3%; gross margin 64.9% vs 61.8%.
- Oncology tests 211,000 (+53.9% YoY); record MRD sequential growth of ~21,500 units.
- Positive cash flow $26.4M in Q3; net loss $(0.64)/share vs $(0.26) YoY.
- Raises FY2025 revenue guidance to $2.18B-2.26B from $2.02B-2.10B.
- FY2025 guidance: gross margin ~62-64%; net cash inflow ~$100M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604821/000110465925107727/0001104659-25-107727-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604821/000110465925107727/tm2529763d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-107727

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer